Alana L Welm

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3071465/publications.pdf

Version: 2024-02-01

77	7,455	76326	74163
papers	citations	40 h-index	75 g-index

84	84	84	12668
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Ligandâ€based Discovery of Novel Small Molecule Inhibitors of RON Receptor Tyrosine Kinase. Molecular Informatics, 2022, 41, .	2.5	4
2	Functional precision oncology: Testing tumors with drugs to identify vulnerabilities and novel combinations. Cancer Cell, 2022, 40, 26-35.	16.8	108
3	Astrocytic laminin-211 drives disseminated breast tumor cell dormancy in brain. Nature Cancer, 2022, 3, 25-42.	13.2	52
4	A human breast cancer-derived xenograft and organoid platform for drug discovery and precision oncology. Nature Cancer, 2022, 3, 232-250.	13.2	133
5	PDXNet portal: patient-derived Xenograft model, data, workflow and tool discovery. NAR Cancer, 2022, 4, zcac014.	3.1	7
6	Improving the odds together: a framework for breast cancer research scientists to include patient advocates in their research. Npj Breast Cancer, 2022, 8, .	5.2	0
7	Singleâ€cell RNA sequencing reveals localized tumour ablation and intratumoural immunostimulant delivery potentiate T cell mediated tumour killing. Clinical and Translational Medicine, 2022, 12, .	4.0	9
8	RON signalling promotes therapeutic resistance in ESR1 mutant breast cancer. British Journal of Cancer, 2021, 124, 191-206.	6.4	16
9	The lingering mysteries of metastatic recurrence in breast cancer. British Journal of Cancer, 2021, 124, 13-26.	6.4	263
10	Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts. Nature Genetics, 2021, 53, 86-99.	21.4	118
11	Heterogeneity in Metastatic Potential of Cancer Cells Is Revealed En Masse. Cancer Cell, 2021, 39, 148-150.	16.8	0
12	Toward improved models of human cancer. APL Bioengineering, 2021, 5, 010901.	6.2	7
13	Blocking Short-Form Ron Eliminates Breast Cancer Metastases through Accumulation of Stem-Like CD4+ T Cells That Subvert Immunosuppression. Cancer Discovery, 2021, 11, 3178-3197.	9.4	7
14	Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidates for targeted treatment. Nature Communications, 2021, 12, 5086.	12.8	58
15	Dll1+ quiescent tumor stem cells drive chemoresistance in breast cancer through NF-Î²B survival pathway. Nature Communications, 2021, 12, 432.	12.8	38
16	An immune-humanized patient-derived xenograft model of estrogen-independent, hormone receptor positive metastatic breast cancer. Breast Cancer Research, 2021, 23, 100.	5.0	20
17	CD229 CAR T Cell Therapy for the Treatment of Relapsed B Cell Lymphoma. Blood, 2021, 138, 2800-2800.	1.4	0
18	Tumoural activation of TLR3â€“SLIT2 axis in endothelium drives metastasis. Nature, 2020, 586, 299-304.	27.8	84

#	Article	IF	Citations
19	Enrichment of Collagen Fragments Using Dimeric Collagen Hybridizing Peptide for Urinary Collagenomics. Journal of Proteome Research, 2020, 19, 2926-2932.	3.7	4
20	A pipeline for identification and validation of tumor-specific antigens in a mouse model of metastatic breast cancer. OncoImmunology, 2020, 9, 1685300.	4.6	8
21	Abstract 1673: Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts. , 2020, , .		3
22	The importance of developing therapies targeting the biological spectrum of metastatic disease. Clinical and Experimental Metastasis, 2019, 36, 305-309.	3.3	9
23	Protective autophagy elicited by RAFâ†'MEKâ†'ERK inhibition suggests a treatment strategy for RAS-driven cancers. Nature Medicine, 2019, 25, 620-627.	30.7	457
24	NetH2pan: A Computational Tool to Guide MHC Peptide Prediction on Murine Tumors. Cancer Immunology Research, 2018, 6, 636-644.	3.4	20
25	EPHB6 augments both development and drug sensitivity of triple-negative breast cancer tumours. Oncogene, 2018, 37, 4073-4093.	5.9	30
26	Understanding the Bone in Cancer Metastasis. Journal of Bone and Mineral Research, 2018, 33, 2099-2113.	2.8	285
27	mTORC1 is a key mediator of RON-dependent breast cancer metastasis with therapeutic potential. Npj Breast Cancer, 2018, 4, 36.	5.2	20
28	Inhibition of RON kinase potentiates anti-CTLA-4 immunotherapy to shrink breast tumors and prevent metastatic outgrowth. OncoImmunology, 2018, 7, e1480286.	4.6	23
29	RON kinase: A target for treatment of cancer-induced bone destruction and osteoporosis. Science Translational Medicine, 2017, 9, .	12.4	58
30	Loss of RasGAP Tumor Suppressors Underlies the Aggressive Nature of Luminal B Breast Cancers. Cancer Discovery, 2017, 7, 202-217.	9.4	57
31	PDX-MI: Minimal Information for Patient-Derived Tumor Xenograft Models. Cancer Research, 2017, 77, e62-e66.	0.9	92
32	O43 Therapeutic vaccination against breast cancer in a transgenic mouse model. Human Immunology, 2017, 78, 40.	2.4	0
33	Proapoptotic PUMA targets stem-like breast cancer cells to suppress metastasis. Journal of Clinical Investigation, 2017, 128, 531-544.	8.2	38
34	Patient-derived xenograft (PDX) models in basic and translational breast cancer research. Cancer and Metastasis Reviews, 2016, 35, 547-573.	5.9	189
35	RON Signaling Is a Key Mediator of Tumor Progression in Many Human Cancers. Cold Spring Harbor Symposia on Quantitative Biology, 2016, 81, 177-188.	1.1	21
36	High Intratumoral Stromal Content Defines Reactive Breast Cancer as a Low-risk Breast Cancer Subtype. Clinical Cancer Research, 2016, 22, 5068-5078.	7.0	38

#	Article	IF	Citations
37	A Biobank of Breast Cancer Explants with Preserved Intra-tumor Heterogeneity to Screen Anticancer Compounds. Cell, 2016, 167, 260-274.e22.	28.9	376
38	Preclinical Evaluation of Fatty Acid Synthase and EGFR Inhibition in Triple-Negative Breast Cancer. Clinical Cancer Research, 2016, 22, 4687-4697.	7.0	62
39	Short-form Ron is a novel determinant of ovarian cancer initiation and progression. Genes and Cancer, 2016, 7, 169-181.	1.9	15
40	Metabolic reprogramming in triple-negative breast cancer through Myc suppression of TXNIP. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 5425-5430.	7.1	190
41	Preclinical Efficacy of Ron Kinase Inhibitors Alone and in Combination with PI3K Inhibitors for Treatment of sfRon-Expressing Breast Cancer Patient-Derived Xenografts. Clinical Cancer Research, 2015, 21, 5588-5600.	7.0	32
42	Invasive Lobular Carcinoma Cell Lines Are Characterized by Unique Estrogen-Mediated Gene Expression Patterns and Altered Tamoxifen Response. Cancer Research, 2014, 74, 1463-1474.	0.9	122
43	The RON Receptor Tyrosine Kinase Promotes Metastasis by Triggering MBD4-Dependent DNA Methylation Reprogramming. Cell Reports, 2014, 6, 141-154.	6.4	48
44	Treatment of Triple-Negative Breast Cancer Using Anti-EGFRâ€“Directed Radioimmunotherapy Combined with Radiosensitizing Chemotherapy and PARP Inhibitor. Journal of Nuclear Medicine, 2013, 54, 913-921.	5.0	66
45	PatientâEDerived Models of Human Breast Cancer: Protocols for In Vitro and In Vivo Applications in Tumor Biology and Translational Medicine. Current Protocols in Pharmacology, 2013, 60, Unit14.23.	4.0	162
46	Inhibition of Ron Kinase Blocks Conversion of Micrometastases to Overt Metastases by Boosting Antitumor Immunity. Cancer Discovery, 2013, 3, 751-760.	9.4	69
47	Survivin promotion of melanoma metastasis requires upregulation of Î± 5 integrin. Carcinogenesis, 2013, 34, 2137-2144.	2.8	36
48	RON promotes the metastatic spread of breast carcinomas by subverting antitumor immune responses. OncoImmunology, 2013, 2, e25670.	4.6	21
49	The EWS/FLI Oncogene Drives Changes in Cellular Morphology, Adhesion, and Migration in Ewing Sarcoma. Genes and Cancer, 2012, 3, 102-116.	1.9	82
50	Mouse models of breast cancer metastasis to bone. Cancer and Metastasis Reviews, 2012, 31, 579-583.	5.9	26
51	On the shoulders of giants: A historical perspective of unique experimental methods in mammary gland research. Seminars in Cell and Developmental Biology, 2012, 23, 583-590.	5.0	7
52	Overview of Human Primary Tumorgraft Models: Comparisons with Traditional Oncology Preclinical Models and the Clinical Relevance and Utility of Primary Tumorgrafts in Basic and Translational Oncology Research. Current Protocols in Pharmacology, 2012, 59, Unit 14.22.	4.0	21
53	Transient Low Doses of DNA-Demethylating Agents Exert Durable Antitumor Effects on Hematological and Epithelial Tumor Cells. Cancer Cell, 2012, 21, 430-446.	16.8	564
54	Blocking Fibroblast Growth Factor Receptor Signaling Inhibits Tumor Growth, Lymphangiogenesis, and Metastasis. PLoS ONE, 2012, 7, e39540.	2.5	39

#	Article	IF	Citations
55	Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes. Nature Medicine, 2011, 17, 1514-1520.	30.7	842
56	Short-Form Ron Promotes Spontaneous Breast Cancer Metastasis through Interaction with Phosphoinositide 3-Kinase. Genes and Cancer, 2011, 2, 753-762.	1.9	41
57	Netrin-4 Activates Endothelial Integrin Î±6Î²1. Circulation Research, 2011, 109, 770-774.	4.5	40
58	Protein Arginine Methyltransferase 5 Accelerates Tumor Growth by Arginine Methylation of the Tumor Suppressor Programmed Cell Death 4. Cancer Research, 2011, 71, 5579-5587.	0.9	126
59	Netrin-4 induces lymphangiogenesis in vivo. Blood, 2010, 115, 5418-5426.	1.4	78
60	A Dominant Mutant Allele of the ING4 Tumor Suppressor Found in Human Cancer Cells Exacerbates MYC-Initiated Mouse Mammary Tumorigenesis. Cancer Research, 2010, 70, 5155-5162.	0.9	29
61	The Macrophage Stimulating Protein/Ron Pathway as a Potential Therapeutic Target to Impede Multiple Mechanisms Involved in Breast Cancer Progression. Current Drug Targets, 2010, 11, 1157-1168.	2.1	52
62	HOXA9 regulates BRCA1 expression to modulate human breast tumor phenotype. Journal of Clinical Investigation, 2010, 120, 1535-1550.	8.2	98
63	Phosphorylation of the src Epithelial Substrate Trask Is Tightly Regulated in Normal Epithelia but Widespread in Many Human Epithelial Cancers. Clinical Cancer Research, 2009, 15, 2311-2322.	7.0	46
64	Six1 expands the mouse mammary epithelial stem/progenitor cell pool and induces mammary tumors that undergo epithelial-mesenchymal transition. Journal of Clinical Investigation, 2009, 119, 2663-2677.	8.2	153
65	The Six1 homeoprotein induces human mammary carcinoma cells to undergo epithelial-mesenchymal transition and metastasis in mice through increasing TGF-Î² signaling. Journal of Clinical Investigation, 2009, 119, 2678-2690.	8.2	209
66	Lentiviral Transduction of Mammary Stem Cells for Analysis of Gene Function during Development and Cancer. Cell Stem Cell, 2008, 2, 90-102.	11.1	171
67	TGFÎ² Primes Breast Tumor Cells for Metastasis. Cell, 2008, 133, 27-28.	28.9	26
68	The macrophage-stimulating protein pathway promotes metastasis in a mouse model for breast cancer and predicts poor prognosis in humans. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 7570-7575.	7.1	126
69	Coordinate expression and functional profiling identify an extracellular proteolytic signaling pathway. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 5771-5776.	7.1	89
70	MET and MYC cooperate in mammary tumorigenesis. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 4324-4329.	7.1	87
71	Cell division and cell survival in the absence of survivin. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 15100-15105.	7.1	172
72	C/EBPÎ± Is Required for Proteolytic Cleavage of Cyclin A by Calpain 3 in Myeloid Precursor Cells. Journal of Biological Chemistry, 2002, 277, 33848-33856.	3.4	28

#	Article	IF	Citations
73	Calreticulin Interacts with C/EBPÎ± and C/EBPÎ² mRNAs and Represses Translation of C/EBP Proteins. Molecular and Cellular Biology, 2002, 22, 7242-7257.	2.3	90
74	C/EBPÎ± Arrests Cell Proliferation through Direct Inhibition of Cdk2 and Cdk4. Molecular Cell, 2001, 8, 817-828.	9.7	312
75	RNA CUG Repeats Sequester CUGBP1 and Alter Protein Levels and Activity of CUGBP1. Journal of Biological Chemistry, 2001, 276, 7820-7826.	3.4	266
76	Translational Induction of Liver-enriched Transcriptional Inhibitory Protein during Acute Phase Response Leads to Repression of CCAAT/Enhancer Binding Protein Î± mRNA. Journal of Biological Chemistry, 2000, 275, 27406-27413.	3.4	39
77	C/EBPÎ± Regulates Generation of C/EBPÎ² Isoforms through Activation of Specific Proteolytic Cleavage. Molecular and Cellular Biology, 1999, 19, 1695-1704.	2.3	102